{"name":"VIVUS LLC","slug":"vivus-llc","ticker":"","exchange":"","domain":"vivusllc.com","description":"","hq":"Mountain View","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2012-01-01","label":"Stendra first approved","drug":"Stendra","drugSlug":"avanafil","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"Stendra","genericName":"AVANAFIL","slug":"avanafil","indication":"Impotence","status":"marketed"},{"name":"VI-0521","genericName":"VI-0521","slug":"vi-0521","indication":"Other","status":"marketed"},{"name":"VI-0521 Mid Dose","genericName":"VI-0521 Mid Dose","slug":"vi-0521-mid-dose","indication":"Other","status":"marketed"},{"name":"Nitrostat","genericName":"Nitrostat","slug":"nitrostat","indication":"Other","status":"marketed"},{"name":"Placebo matched phentermine/topiramate","genericName":"Placebo matched phentermine/topiramate","slug":"placebo-matched-phentermine-topiramate","indication":"Chronic weight management in obese or overweight patients with weight-related comorbidities","status":"phase_3"},{"name":"Stendra 200 mg","genericName":"Stendra 200 mg","slug":"stendra-200-mg","indication":"Other","status":"marketed"},{"name":"avanafil 200mg","genericName":"avanafil 200mg","slug":"avanafil-200mg","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Phentermine and Topiramate","genericName":"Phentermine and Topiramate","slug":"phentermine-and-topiramate","indication":"Obesity Management","status":"marketed"},{"name":"VI-0521 Top Dose","genericName":"VI-0521 Top Dose","slug":"vi-0521-top-dose","indication":"Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"BiCNU","genericName":"BiCNU","slug":"bicnu","indication":"Hodgkin's lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"Stendra","genericName":"AVANAFIL","slug":"avanafil","phase":"marketed","mechanism":"Stendra works by inhibiting an enzyme that breaks down a molecule called cyclic GMP, allowing blood vessels to relax and improve blood flow to the penis.","indications":["Impotence"],"catalyst":""},{"name":"VI-0521","genericName":"VI-0521","slug":"vi-0521","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VI-0521 Mid Dose","genericName":"VI-0521 Mid Dose","slug":"vi-0521-mid-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BiCNU","genericName":"BiCNU","slug":"bicnu","phase":"phase_2","mechanism":"BiCNU is a chemotherapy medication that works by interfering with DNA replication and cell division.","indications":["Hodgkin's lymphoma","Non-Hodgkin's lymphoma","Ovarian cancer","Breast cancer","Testicular cancer"],"catalyst":""},{"name":"Nitrostat","genericName":"Nitrostat","slug":"nitrostat","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phentermine and Topiramate","genericName":"Phentermine and Topiramate","slug":"phentermine-and-topiramate","phase":"marketed","mechanism":"Phentermine and topiramate reduce appetite and food consumption through different mechanisms involving catecholamine release and neurotransmitter modulation.","indications":["Obesity Management","Overweight with Comorbidity Management"],"catalyst":""},{"name":"Placebo matched phentermine/topiramate","genericName":"Placebo matched phentermine/topiramate","slug":"placebo-matched-phentermine-topiramate","phase":"phase_3","mechanism":"Phentermine/topiramate is a combination that suppresses appetite through sympathomimetic stimulation and enhances satiety through carbonic anhydrase inhibition and GABAergic effects.","indications":["Chronic weight management in obese or overweight patients with weight-related comorbidities"],"catalyst":""},{"name":"Stendra 200 mg","genericName":"Stendra 200 mg","slug":"stendra-200-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VI-0521 Top Dose","genericName":"VI-0521 Top Dose","slug":"vi-0521-top-dose","phase":"marketed","mechanism":"VI-0521 is a phentermine-based combination product that acts as a sympathomimetic amine to suppress appetite and increase energy expenditure for weight management.","indications":["Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities"],"catalyst":""},{"name":"avanafil 200mg","genericName":"avanafil 200mg","slug":"avanafil-200mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPWkZKbS14RDhSMFFmOFAtMFNQdTlFN2M0dGgyemMtNEx5ZGhzU00wS2RYN0N4YzRnLUpfdm5tazVQMEpBQ3hTMXFTUm52UmhpMENSVnZ4NEVGcldCMnZ6S0RPcnhhWk1lVC1GWnE0cnp2QkRSMnpmRXY4VDBsa2FNYTBQS2VuQ1RhdzFYSw?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"VIVUS Announces QSYMIA® Price Reduction at Costco Pharmacies Nationwide - Yahoo Finance","headline":"VIVUS Announces QSYMIA® Price Reduction at Costco Pharmacies Nationwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1kOEhwMmNMRjdHX2JRaGhudDR1enVjWUtJTzczd3E2b3dfaWk1anZBa1M2c1ZOWS02TWlPcHEwLXJueXZLdjFPWExZbmNQdlZrTTR0Mi1wbVI2OWxQZUxwTlRWT29uOEYtbXZoaDU2cTYzdEZR?oc=5","date":"2025-09-14","type":"pipeline","source":"Marin Independent Journal","summary":"Mark Seiji Hanamoto Obituary - Belmont, CA (1950-2025) - Marin Independent Journal","headline":"Mark Seiji Hanamoto Obituary - Belmont, CA (1950-2025)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9DaWxkaF93MmFrZEhHcVY5SkVxYS1XRUtQMzJZVWRNTWdtM1Rfa0hiaHNERDhySEYyR3Y5NVJxMDg0bFk2YXVXUkZ2Z2tGbzRIdkFRWEFPb04wR3g3RWpVY2U3R1FHcU5QelE?oc=5","date":"2025-06-26","type":"pipeline","source":"Market.us","summary":"Anti-obesity Drugs Market Growth Trend Analysis | CAGR of 31.7% - Market.us","headline":"Anti-obesity Drugs Market Growth Trend Analysis | CAGR of 31.7%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOVTVxdnMwNkdPSTg3NU1kdG9uVExSSFpNb2E4T200MDFSMVBYVTgtam04NlYyQ2pDdDY3MlhrMEFKUHpmbkM2NWxZZEZmeEdZYzN4Qlo2VGppbTFrMFludlllQW4zWnJLMzMwNEhaQ1NaeWlXN2FuNThqaU9lV3FmRDdzbkRXTnc?oc=5","date":"2025-01-13","type":"pipeline","source":"Yahoo Finance","summary":"VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Yahoo Finance","headline":"VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 20","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVWZSbXc0UlQwQXRCTFh4OFNHX1VFOU96R1pOR2VkTGFmR2VVTV9CblZvRzdhMGRkWXM3czFCR2NNMnkxeXZZbjFPeVlja0s4X0RRWURNM2I5RHFQb1pWOHROdkpRWGZ1WkpkNWNDZGRRVDgzMXBoUXExM3otOHVjUERUUkxjOUxJejVVQjlZdU83YVNWMFRNTHBZVk9zU05yazBRa2RXOTJ1VWx4ZDdHSUlrRQ?oc=5","date":"2024-12-09","type":"pipeline","source":"Stock Titan","summary":"Achieve Life Sciences Taps Biotech Veteran Mark Oki as New CFO to Lead Financial Strategy - Stock Titan","headline":"Achieve Life Sciences Taps Biotech Veteran Mark Oki as New CFO to Lead Financial Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOYWdxYmc5X3pFaVFsaFI1QjhvbkxOUXRjLW0za2c3SVFkcVdCa1V2Q0RVNjc3WWFPdTFDbjA0SU1vQUJCbXA0SHA2NVNydnFxSzZXSlZqSFpiV1l6WkZQTkR6X1BWUDZDUFNRODRqck5lbU9jdGZHb1laX2xxbjJSZGxkVDdNV1NvenpuU3FTZnRCcENnOG1QbUhpUEJXUml5Vm5veXhpVzVrTjl5YnRwakNrcGhuUWZVODA4MlVIajdaVG85bVg4SU5qdUxWWkVHTllLak01RFZFZEZDWW1fckhmNkxacUZVRDA2dUhwdURzaWY5TDVuSmd3?oc=5","date":"2024-10-07","type":"pipeline","source":"GlobeNewswire","summary":"VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland - GlobeNewswire","headline":"VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBXX2J6ZWFBSTlqQTFIeXkzWmN5bWw1SDgzOVBoSVdGS3hoLWhfRkxWQlhjMXg0dlJRRzZEa0hxczdXU016NDdjQXdNOEYxbDV0MUhrcEFySkNZbDR3SzBCQWE2cEZId2prUVJGeF9XMmN5SkE?oc=5","date":"2024-05-08","type":"regulatory","source":"Straits Research","summary":"Anti-obesity Medication Market Size, Top Share, Demand | Industry Report, 2034 - Straits Research","headline":"Anti-obesity Medication Market Size, Top Share, Demand | Industry Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPc2ZWcFZBaEZ2QUtPcllfT0J2d1pUVjQ3NnJKZ3ljeHcyc0xGcUIyc1JKbzZVd285Qm9UWUhxSUozejk0ZW9hQ0FBN1A1Y01Udk85LXJxZWxYSjRnMjNQR1huVkU1eC14bjlfZ3NNRGRTb2J0eWJ0MmxMOGJGVnI0OElPY19VbmpBVE5fSTlSMjhKRm9seDNrMHczTGt0YjRaOXQ1UmUwQjc2QXd0OFkzaVpkcE1PdFlMRVdLQkd3N3FsSzNONGU4?oc=5","date":"2024-01-08","type":"pipeline","source":"GlobeNewswire","summary":"VIVUS Provides Update on Pipeline and Program Milestones - GlobeNewswire","headline":"VIVUS Provides Update on Pipeline and Program Milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQU3EtZzd4UDJjMlpQQVc5VXh4SXBURy10U2M3Wkt2X3FGR0VOdnR3N3RHeFR3YWVUbFJIbXliUlBUQW14YUNCbDR5blR2TFo5VXZFODM2UGJ1N21rQ1RNY19CdUxpdVh3SzEtWWttdXZXckdnb1dxMkxDVFh1akNNbm93?oc=5","date":"2023-12-28","type":"pipeline","source":"Fortune Business Insights","summary":"U.S. Anti-obesity Drugs Market Size | Growth Report [2032] - Fortune Business Insights","headline":"U.S. Anti-obesity Drugs Market Size | Growth Report [2032]","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-19","type":"pipeline","source":"prnewswire.com","summary":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B","headline":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPcGowRXdOeG5PejRuNmlHVG9waFpOMVNVU0JtNEttanFhSF9vREtUdzRpV04tVVdVQ2ZsUUdQWE80WkxKVmtUTk1udU9SdU5IQ1pta0JPRVFBY2ZjVWNha3o1UFVWR3ZlQzJGVGpxZTBSUnVXNlZ6a1cycFZsdllOdUtUeExvZklXSUZLZ2dHZlJScXJDazdLTFRR?oc=5","date":"2020-07-07","type":"deal","source":"WSJ","summary":"Drugmaker Vivus Files for Bankruptcy in Deal With IEH - WSJ","headline":"Drugmaker Vivus Files for Bankruptcy in Deal With IEH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOTEpjX0tXMDJRVFJDUUlzWHBaYUN1NUk4WXdYei1QYjRIcFpEN3FzRlJkdU5FQXNjWWQ2eF84cTg5aTl5dV9IRE1GalJGUDJjeWV5TmlSSVJmQ2NfdllnU3dQZEZENEJ6dkNvLXd3UUFBa2hjZl9mZWphSkkyU3NHRGRzT0FhamdEUXhjbGNWQ1MwcGhSc2FNX0hILV9JNjdmWHRWRkZTOVVCN2gyazJ0SnFubEE?oc=5","date":"2017-03-29","type":"pipeline","source":"Fierce Pharma","summary":"Sanofi, following in Endo's footsteps, hands back rights to Vivus on ED med Stendra - Fierce Pharma","headline":"Sanofi, following in Endo's footsteps, hands back rights to Vivus on ED med Stendra","sentiment":"neutral"}],"patents":[],"drugCount":10,"phaseCounts":{"marketed":7,"phase_2":1,"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}